Advertisement

Cancer Anorexia (CA)

  • Nagi B. Kumar
Chapter

Abstract

Anorexia can be defined as a lack of appetite or loss of desire to eat resulting in the involuntary decline in food intake contributing to malnutrition. Although cancer cachexia and cancer anorexia have been used synonymously in research literature, there are distinct differences between the two symptoms observed in cancer patient populations. In cancer anorexia, without cachexia, metabolism is almost normal, and nutritional deficits and symptom management can be achieved. If a patient with cancer anorexia continues to develop or demonstrate persistent metabolic disturbances, it is likely that this patient is cachectic and should be screened, staged, and treated for cancer cachexia with anorexia.

Keywords

Lean Body Mass Physical Activity Intervention Symptom Cluster Nutritional Intake Cancer Cachexia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, Reddy K, Hastings S, Exterman M, Balducci L, Dalton K, Bepler G (2010) Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol 11(3–4):107–117, ReviewPubMedCrossRefGoogle Scholar
  2. 2.
    Gupta SC, Kim JH, Kannappan R, Reuter S, Dougherty PM, Aggarwal BB (2011) Role of nuclear factor κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med (Maywood) 236(6):658–671, Epub 2011 May 12. ReviewCrossRefGoogle Scholar
  3. 3.
    Tisdale MJ (2008) Catabolic mediators of cancer cachexia. Curr Opin Support Palliat Care 2(4):256–261, PMID: 19069310PubMedCrossRefGoogle Scholar
  4. 4.
    Deans C, Wigmore SJ (2005) Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 8(3):265–269, PMID: 15809528PubMedCrossRefGoogle Scholar
  5. 5.
    Tisdale MJ (2001) Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci 6:164–174, PMID: 11171557CrossRefGoogle Scholar
  6. 6.
    Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, Gouma DJ, Giacosa A, Van Gossum A, Bauer J, Barber MD, Aaronson NK, Voss AC, Tisdale MJ (2003) Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52(10):1479–1486, PMCID: PMC1773823PubMedCrossRefGoogle Scholar
  7. 7.
    Tisdale MJ (1999) Wasting in cancer. J Nutr 129(1S Suppl):243S–246S, Review. PMID: 9915907PubMedGoogle Scholar
  8. 8.
    Morley JE (2002) Pathophysiology of anorexia. Clin Geriatr Med 18(4):661–673, v. Review. PMID: 12608495PubMedCrossRefGoogle Scholar
  9. 9.
    Shoemaker LK, Estfan B, Induru R, Walsh TD (2011) Symptom management: an important part of cancer care. Cleve Clin J Med 78(1):25–34PubMedCrossRefGoogle Scholar
  10. 10.
    Von Roenn JH (1994) Randomized trials of megestrol acetate for AIDS-associated anorexia and cachexia. Oncology 51(Suppl 1):19–24CrossRefGoogle Scholar
  11. 11.
    Khalid U, Spiro A, Baldwin C, Sharma B, McGough C, Norman AR, Eisen T, O’Brien ME, Cunningham D, Andreyev HJ (2007) Symptoms and weight loss in patients with gastrointestinal and lung cancer at presentation. Support Care Cancer 15(1):39–46PubMedCrossRefGoogle Scholar
  12. 12.
    Van Cutsem E, Arends J (2005) The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 9(Suppl 2):S51–S63PubMedCrossRefGoogle Scholar
  13. 13.
    Schmitz KH, Holtzman J, Courneya KS, Mâsse LC, Duval S, Kane R (2005) Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 14:1588–1595PubMedCrossRefGoogle Scholar
  14. 14.
    Copland L, Liedman B, Rothenberg E, Bosaeus I (2007) Effects of nutritional support long time after total gastrectomy. Clin Nutr 26:605–613PubMedCrossRefGoogle Scholar
  15. 15.
    Braga M, Molinari M, Zuliani W, Foppa L, Gianotti L, Radaelli G, Cristallo M, Di Carlo V (1996) Surgical treatment of gastric adenocarcinoma: impact on survival and quality of life. A prospective ten year study. Hepatogastroenterology 43:187–193PubMedGoogle Scholar
  16. 16.
    Hyltander A, Bosaeus I, Svedlund J, Liedman B, Hugosson I, Wallengren O, Olsson U, Johnsson E, Kostic S, Henningsson A et al (2005) Supportive nutrition on recovery of metabolism, nutritional state, health-related quality of life, and exercise capacity after major surgery: a randomized study. Clin Gastroenterol Hepatol 3:466–474PubMedCrossRefGoogle Scholar
  17. 17.
    Liedman B, Andersson H, Berglund B, Bosaeus I, Hugosson I, Olbe L, Lundell L (1996) Food intake after gastrectomy for gastric carcinoma: the role of a gastric reservoir. Br J Surg 83:1138–1143PubMedCrossRefGoogle Scholar
  18. 18.
    Takahashi S, Maeta M, Mizusawa K, Kaneko T, Naka T, Ashida K, Tsujitani S, Kaibara N (1998) Long-term postoperative analysis of nutritional status after limited gastrectomy for early gastric cancer. Hepatogastroenterology 45:889–894PubMedGoogle Scholar
  19. 19.
    García-Peris P, Parón L, Velasco C, de la Cuerda C, Camblor M, Bretón I, Herencia H, Verdaguer J, Navarro C, Clave P (2007) Long-term prevalence of oropharyngeal dysphagia in head and neck cancer patients: impact on quality of life. Clin Nutr 26(6):710–717, Epub 2007 Oct 22PubMedCrossRefGoogle Scholar
  20. 20.
    Couch M, Lai V, Cannon T, Guttridge D, Zanation A, George J, Hayes DN, Zeisel S, Shores C (2007) Cancer cachexia syndrome in head and neck cancer patients: part I. Diagnosis, impact on quality of life and survival, and treatment. Head Neck 29(4):401–411, PMID: 17285641PubMedCrossRefGoogle Scholar
  21. 21.
    Malone FR, Leisenring WM, Storer BE, Lawler R, Stern JM, Aker SN, Bouvier ME, Martin PJ, Batchelder AL, Schoch HG, McDonald GB (2007) Prolonged anorexia and elevated plasma cytokine levels following myeloablative allogeneic hematopoietic cell transplant. Bone Marrow Transplant 40(8):765–772, Epub 2007 Aug 13PubMedCrossRefGoogle Scholar
  22. 22.
    Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlina C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491–497, PMID: 7424938PubMedCrossRefGoogle Scholar
  23. 23.
    Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE, O’Brien ME (2004) Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 90:1905–1911PubMedCrossRefGoogle Scholar
  24. 24.
    Vallas B, Lauque S, Andrieu S, Nurhashemi F, Folland Y, Baumgartner R, Garry P (2001) Nutrition assessment in the elderly. Curr Opin Clin Nutr Metab Care 4(1):5–8CrossRefGoogle Scholar
  25. 25.
    Morley JE (2003) Anorexia and weight loss in older persons. J Gerontol A Biol Sci Med Sci 58(2):131–137PubMedCrossRefGoogle Scholar
  26. 26.
    Ockenga J, Valentini L (2005) Review article: anorexia and cachexia in gastrointestinal cancer. Aliment Pharmacol Ther 22(7):583–594, ReviewPubMedCrossRefGoogle Scholar
  27. 27.
    Capra S, Ferguson M, Ried K (2001) Cancer: impact of nutrition intervention outcome–­nutrition issues for patients. Nutrition 17:769–772PubMedCrossRefGoogle Scholar
  28. 28.
    Sink J, Kademani D (2011) Maxillofacial oncology at the University of Minnesota: treating the epidemic of oral cancer. Northwest Dent 90(3):13–16, 38PubMedGoogle Scholar
  29. 29.
    Arias F, Manterola A, Domínguez MA, Martínez E, Villafranca E, Romero P, Vera R (2004) Acute dysphagia of oncological origin. Therapeutic management. An Sist Sanit Navar 27(Suppl 3):109–115PubMedGoogle Scholar
  30. 30.
    Davis MP, Walsh D, Lagman R, Yavuzsen T (2006) Early satiety in cancer patients: a common and important but underrecognized symptom. Support Care Cancer 14(7):693–698, Epub 2006 Apr 20. ReviewPubMedCrossRefGoogle Scholar
  31. 31.
    Ryu SW, Kim IH (2010) Comparison of different nutritional assessments in detecting malnutrition among gastric cancer patients. World J Gastroenterol 16(26):3310–3317PubMedCrossRefGoogle Scholar
  32. 32.
    Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404:661–671PubMedGoogle Scholar
  33. 33.
    Plata-Salaman CR (1996) Anorexia during acute and chronic disease. Nutrition 12:69–78PubMedCrossRefGoogle Scholar
  34. 34.
    Laviano A, Meguid MM, Rossi-Fanelli F (2003) Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 4:686–694PubMedCrossRefGoogle Scholar
  35. 35.
    Mantovani G, Macciò A, Esu S, Lai P, Santona MC, Massa E, Dessì D, Melis G, Del Giacco S (1997) Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Biochem Soc Trans 25(2):296SPubMedGoogle Scholar
  36. 36.
    Barrett GL, Naim T, Trieu J (2011) Leptin-derived peptides that stimulate food intake and increase body weight following peripheral administration. Regul Pept 170(1–3):24–30, Epub 2011 May 24PubMedCrossRefGoogle Scholar
  37. 37.
    Opara EI, Laviano A, Meguid MM, Yang ZJ (1995) Correlation between food intake and CSF IL-1 alpha in anorectic tumor bearing rats. Neuroreport 6:750–752PubMedCrossRefGoogle Scholar
  38. 38.
    Laviano A, Gleason JR, Meguid MM, Yang ZJ, Cangiano C, Rossi Fanelli F (2000) Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. J Invest Med 48:40–48Google Scholar
  39. 39.
    Wood LJ, Nail LM, Perrin NA, Elsea CR, Fischer A, Druker BJ (2006) The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biol Res Nurs 8:157–169PubMedCrossRefGoogle Scholar
  40. 40.
    Wang W, Lonnroth C, Svanberg E, Lundholm K (2001) Cytokine and cyclooxygenase-2 protein in brain areas of tumor-bearing mice with prostanoid-related anorexia. Cancer Res 61:4707–4715PubMedGoogle Scholar
  41. 41.
    Hopkinson JB (2010) The emotional aspects of cancer anorexia. Curr Opin Support Palliat Care 4(4):254–258, ReviewPubMedCrossRefGoogle Scholar
  42. 42.
    Hopkinson JB, Brown JC, Okamoto I, Addington-Hall JM (2012) The effectiveness of ­patient-family carer (couple) intervention for the management of symptoms and other ­health-related problems in people affected by cancer: a systematic literature search and ­narrative review. J Pain Symptom Manage 43(1):111–142, Epub 2011 Jun 30Google Scholar
  43. 43.
    Thomas DR (2009) Anorexia: aetiology, epidemiology and management in older people. Drugs Aging 26(7):557–570PubMedCrossRefGoogle Scholar
  44. 44.
    Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489–495, Epub 2011 Feb 4. ReviewPubMedCrossRefGoogle Scholar
  45. 45.
    Dy SM, Lorenz KA, O’Neill SM, Asch SM, Walling AM, Tisnado D, Antonio AL, Malin JL (2010) Cancer Quality-ASSIST supportive oncology quality indicator set: feasibility, reliability, and validity testing. Cancer 116(13):3267–3275PubMedCrossRefGoogle Scholar
  46. 46.
    Townsend D, Accurso-Massana C, Lechman C, Duder S, Chasen M (2010) Cancer nutrition rehabilitation program: the role of social work. Curr Oncol 17(6):12–17PubMedCrossRefGoogle Scholar
  47. 47.
    Ramic E, Pranjic N, Batic-Mujanovic O, Karic E, Alibasic E, Alic A (2011) The effect of loneliness on malnutrition in elderly population. Med Arh 65(2):92–95PubMedGoogle Scholar
  48. 48.
    McQuestion M, Fitch M, Howell D (2011) The changed meaning of food: physical, social and emotional loss for patients having received radiation treatment for head and neck cancer. Eur J Oncol Nurs 15(2):145–151PubMedCrossRefGoogle Scholar
  49. 49.
    Snyder CF, Garrett-Mayer E, Blackford AL, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW (2009) Concordance of cancer patients’ function, symptoms, and supportive care needs. Qual Life Res 18(8):991–998, Epub 2009 Aug 6PubMedCrossRefGoogle Scholar
  50. 50.
    Jiménez A, Madero R, Alonso A, Martínez-Marín V, Vilches Y, Martínez B, Feliu M, Díaz L, Espinosa E, Feliu J (2011) Symptom clusters in advanced cancer. J Pain Symptom Manage 42(1):24–31, Epub 2011 Mar 12PubMedCrossRefGoogle Scholar
  51. 51.
    Kirkova J, Aktas A, Walsh D, Davis MP (2011) Cancer symptom clusters: clinical and research methodology. J Palliat Med 14(10):1149–1166, Epub 2011 Aug 23PubMedCrossRefGoogle Scholar
  52. 52.
    Laviano A, Seelaender M, Sanchez-Lara K, Gioulbasanis I, Molfino A, Rossi Fanelli F (2011) Beyond anorexia -cachexia. Nutrition and modulation of cancer patients’ metabolism: supplementary, complementary or alternative anti-neoplastic therapy? Eur J Pharmacol 668(Suppl 1):S87–S90, Epub 2011 Jul 27Google Scholar
  53. 53.
    Paccagnella A, Morassutti I, Rosti G (2011) Nutritional intervention for improving treatment tolerance in cancer patients. Curr Opin Oncol 23(4):322–330PubMedCrossRefGoogle Scholar
  54. 54.
    Del Fabbro E, Hui D, Dalal S, Dev R, Noorhuddin Z, Bruera E (2011) Clinical outcomes and contributors to weight loss in a cancer cachexia clinic. J Palliat Med 14(9):1004–1008 [Epub ahead of print]PubMedCrossRefGoogle Scholar
  55. 55.
    Baker A, Wooten LA, Malloy M (2011) Nutritional considerations after gastrectomy and esophagectomy for malignancy. Curr Treat Options Oncol 12(1):85–95, Review. Erratum in: Curr Treat Options Oncol. 2011 Mar;12(1):109PubMedCrossRefGoogle Scholar
  56. 56.
    Inui A (2005) Recent development in research and management of cancer anorexia-cachexia syndrome. Gan To Kagaku Ryoho 32(6):743–749, ReviewPubMedGoogle Scholar
  57. 57.
    Ovesen L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP (1993) Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 11:2043–2049, PMID: 8410128PubMedGoogle Scholar
  58. 58.
    Berenstein EG, Ortiz Z (2005) Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev (2):CD004310Google Scholar
  59. 59.
    Leśniak W, Bała M, Jaeschke R, Krzakowski M (2008) Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome–a systematic review and meta-analysis. Pol Arch Med Wewn 118(11):636–644PubMedGoogle Scholar
  60. 60.
    Yeh SS, Lovitt S, Schuster MW (2009) Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly. J Nutr Health Aging 13(5):448–454PubMedCrossRefGoogle Scholar
  61. 61.
    Busquets S, Serpe R, Sirisi S, Toledo M, Coutinho J, Martínez R, Orpí M, López-Soriano FJ, Argilés JM (2010) Megestrol acetate: its impact on muscle protein metabolism supports its use in cancer cachexia. Clin Nutr 29(6):733–737PubMedCrossRefGoogle Scholar
  62. 62.
    Desport JC, Gory-Dalabaere G, Blanc-Vincent MP, Bachmann P, Béal J, Benamouzig R, Colomb V, Kere D, Melchior JC, Nitenberg G, Raynard B, Schneider S, Senesse P, FNCLCC (2003) Standards, options and recommendations for the use of appetite stimulants in oncology (2000). Br J Cancer 89(Suppl 1):S98–S100, PMID: 12915909PubMedCrossRefGoogle Scholar
  63. 63.
    Karcic E, Philpot C, Morley JE (2002) Treating malnutrition with megestrol acetate: literature review and review of our experience. J Nutr Health Aging 6(3):191–200, Review. PMID: 12152625PubMedGoogle Scholar
  64. 64.
    Morley JE (2002) Orexigenic and anabolic agents. Clin Geriatr Med 18(4):853–866, Review. PMID: 12608509PubMedCrossRefGoogle Scholar
  65. 65.
    Donnelly S, Walsh TD (1995) Low-dose megestrol acetate for appetite stimulation in advanced cancer. J Pain Symptom Manage 10:182–183PubMedCrossRefGoogle Scholar
  66. 66.
    Mulligan K, Zackin R, Von Roenn JH et al (2007) ACTG 313 study team. Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab 92:563–570, AbstractPubMedCrossRefGoogle Scholar
  67. 67.
    Navari RM, Brenner MC (2010) Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer 18:951–956PubMedCrossRefGoogle Scholar
  68. 68.
    Walsh D, Kirkova J, Davis MP (2005) The efficacy and tolerability of long-term use of dronabinol in cancer-related anorexia: a case series. J Pain Symptom Manage 30:493–495PubMedCrossRefGoogle Scholar
  69. 69.
    Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D, Possinger K et al (2006) Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24:3394–3400PubMedCrossRefGoogle Scholar
  70. 70.
    Kumar NB, Hopkins K (2007) A retrospective study of Nutritional supplementation and appetite stimulants in the treatment of cancer cachexia. Abstract. In: Proceedings of research day, Moffitt Cancer Center, Tampa, Fl, USA 2007Google Scholar
  71. 71.
    Jatoi A, Windschitl HE, Loprinzi CL et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20:567–573PubMedCrossRefGoogle Scholar
  72. 72.
    Fearon KC (2008) Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 44(8):1124–1132, Epub 2008 Mar 28. PMID: 183475115PubMedCrossRefGoogle Scholar
  73. 73.
    Walsh D, Nelson KA, Mahmoud FA (2003) Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11(3):137–143, Epub 2002 Aug 21. Review. PMID: 12618922PubMedGoogle Scholar
  74. 74.
    Al-Majid S, Waters H (2008) The biological mechanisms of cancer-related skeletal muscle wasting: the role of progressive resistance exercise. Biol Res Nurs 10(1):7–20PubMedCrossRefGoogle Scholar
  75. 75.
    Al-Majid S, McCarthy DO (2001) Cancer-induced fatigue and skeletal muscle wasting: the role of exercise. Biol Res Nurs 2(3):186–197PubMedCrossRefGoogle Scholar
  76. 76.
    Lowe SS (2011) Physical activity and palliative cancer care. Recent Results Cancer Res 186:349–365PubMedCrossRefGoogle Scholar
  77. 77.
    Penna F, Busquets S, Pin F, Toledo M, Baccino FM, López-Soriano FJ, Costelli P, Argilés JM (2011) Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. J Cachex Sarcopenia Muscle 2(2):95–104, Epub 2011 May 11CrossRefGoogle Scholar
  78. 78.
    Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT (1993) The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ 306(6890):1440–1444CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.University of South FloridaTampaUSA

Personalised recommendations